Assessing workforce needs for the emerging CAR-T cell therapy industry

The complicated and labor-intensive manufacturing of novel cell and gene therapies requires efforts to improve workforce development programs for the nascent cell therapy industry broadly, and for cell manufacturing more specifically.

Saved in:
Bibliographic Details
Published in:Nature biotechnology 2022-02, Vol.40 (2), p.275-278
Main Authors: Ho, Linda D, Robbins, Hadassah L, Levine, Aaron D
Format: Article
Language:English
Subjects:
Careers
Cell therapy
COVID-19
Data collection
Datasets
Employment
FDA approval
Gene therapy
Job classification
Job titles
Laboratories
Lymphocytes
Lymphocytes T
Manufacturing
Marketing
Pandemics
Production planning
Regulatory approval
Roles
Workforce
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The complicated and labor-intensive manufacturing of novel cell and gene therapies requires efforts to improve workforce development programs for the nascent cell therapy industry broadly, and for cell manufacturing more specifically.
ISSN:1087-0156
1546-1696
DOI:10.1038/s41587-022-01212-6